An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
Clinical trial NCT04820309 · COMPLETED
Trial details
- NCT number
- NCT04820309
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-02
- Primary completion
- 2024-05-24
- Enrollment
- 566
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.